Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen

Technology appraisal guidance
Reference number: TA316
Published: 23 July 2014

Royal College of Physicians: response to scrutiny letter

Royal College of Physicians: response to scrutiny letter

Royal College of Physicians: response to scrutiny letter
23 July 2014
(518.48 Kb 31 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 22 July 2014